The Role of Chemotherapy and Novel Combinations in Triple Negative Breast Cancer

In the metastatic breast cancer sphere, 2 chemotherapy agents have come to the forefront: capecitabine, for metastatic breast cancer, and eribulin, for triple-negative breast cancer.

Treatment options for triple-negative breast cancer are historically limited; however, recent developments regarding the use of targeted therapies and various combination regimens have broadened the treatment spectrum and ushered in new clinical approaches.

Joseph Gligorov, MD, PhD, discusses potential challenges of utilizing PARP inhibitors in triple-negative breast cancer.

John Crown, BCh, BAO, BSc, MD, MBA, discusses the role of eribulin mesylate in triple-negative breast cancer.

Adam M. Brufsky, MD, PhD, discusses the future role of chemotherapy in triple-negative breast cancer.